Integration of external control data, with patient-level information, in clinical trials has the
potential to accelerate the development of new treatments in neuro-oncology by …

Background External control (EC) data from completed clinical trials and electronic health
records can be valuable for the design and analysis of future clinical trials. We discuss the …

Purpose: We discuss designs and interpretable metrics of bias and statistical efficiency of
“externally controlled” trials (ECT) and compare ECT performance to randomized and single …

Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics
are currently available, and much effort has been expended to identify new drugs capable of …

Building on an initiative to enhance clinical trial participation involving the Society for Neuro-
Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy …

There is a growing focus on making clinical trials more inclusive but the design of trial
eligibility criteria remains challenging,–. Here we systematically evaluate the effect of …

Background There have been few treatment advances for patients with glioblastoma (GBM)
despite increasing scientific understanding of the disease. While factors such as intrinsic …

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …

Randomized controlled trials (RCTs) that assess overall survival are considered the “gold
standard” when evaluating the efficacy and safety of a new oncology intervention. However …

PURPOSE Adequately prioritizing the numerous therapies and biomarkers available in late-
stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing …